AstraZeneca Investing $300 M in New Cell-Therapy Mfg Facility
AstraZeneca has announced plans to invest $300 million in a new cell-therapy manufacturing facility in Rockville, Maryland, for clinical and commercial supply. The facility will initially focus on manufacturing T-cell therapies for clinical supply.
The Rockville facility will join AstraZeneca’s global manufacturing and supply network of nearly 30 manufacturing and supply sites in 16 countries, which are either currently operational or under development, In the US, AstraZeneca’s manufacturing sites focus on the production of small molecules and biologics.
Its US manufacturing sites employ more than 2,600 full-time employees and produce more than 9 billion doses of medicines annually. The new facility will add more than 150 new jobs.